MAS1 and cancer: The concept of saRNA‐mediated gene activation was first described in 2006.[5] saRNA technology provided a new and promising tool for selectively promoting gene transcription in precision medicine.[17] However, saRNA has garnered attention only recently after the successful clinical trial of the first saRNA drug candidate (MTL‐CEBPA) for advanced liver cancer.[7, 18] Herein, we show that saRNAs developed against MAS1 and delivered by the dendrimer vector AD can consistently upregulate MAS1 expression in multiple cancer cell lines, xenograft models, and patient‐derived organoids.